In Segment C, participants will receive ABBV-744 and oral navitoclax. In Segment D, participants will obtain ABBV-744 and ruxolitinib. Individuals will receive treatment right until illness progression or even the participants are unable to tolerate the study drugs. Overall, our latest work highlights the potential utilization of ARV-825 in combination https://marcodsepa.snack-blog.com/31874871/about-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc